02542nas a2200253 4500008004100000022001400041245011600055210006900171260001600240520174000256100001601996700002202012700002402034700002102058700002202079700002202101700002202123700001802145700002102163700002002184700002802204700002002232856003602252 2023 eng d a1758-535X00aAssociation of a blood-based aging biomarker index with death and chronic disease: Cardiovascular Health Study.0 aAssociation of a bloodbased aging biomarker index with death and c2023 Jul 193 a

BACKGROUND: A goal of gerontology is to discover phenotypes that reflect biological aging distinct from disease pathogenesis. Biomarkers that are strongly associated with mortality could be used to define such a phenotype. However, the relation of such an index with multiple chronic conditions warrants further exploration.

METHODS: A Biomarker Index (BI) was constructed in the Cardiovascular Health Study (N=3197), with a mean age of 74 years. The BI incorporated circulating levels of new biomarkers, including insulin-like growth factor-1, interleukin-6, amino-terminal pro-B-type natriuretic peptide, cystatin-C, C-reactive protein, tumor necrosis factor-alpha soluble receptor 1, fasting insulin, and fasting glucose, and was built based on their relationships with mortality. Cox proportional hazards models predicting a composite of death and chronic disease involving cardiovascular disease, dementia, and cancer were calculated with 6 years of follow-up.

RESULTS: The hazard ratio (HR, 95% CI) for the composite outcome of death or chronic disease per category of BI was 1.65 (1.52, 1.80) and 1.75 (1.58, 1.94) in women and men, respectively. The HR (95% CI) per 5 years of age was 1.57 (1.48, 1.67) and 1.55 (1.44, 1.67) in women and men, respectively. Moreover, BI could attenuate the effect of age on the composite outcome by 16.7% and 22.0% in women and men, respectively.

CONCLUSIONS: BI was significantly and independently associated with a composite outcome of death and chronic disease, and attenuated the effect of age. The BI that is composed of plasma biomarkers may be a practical intermediate phenotype for interventions aiming to modify the course of aging.

1 aZhang, Xiao1 aSanders, Jason, L1 aBoudreau, Robert, M1 aArnold, Alice, M1 aJustice, Jamie, N1 aEspeland, Mark, A1 aKuchel, George, A1 aBarzilai, Nir1 aKuller, Lewis, H1 aLopez, Oscar, L1 aKritchevsky, Stephen, B1 aNewman, Anne, B uhttps://chs-nhlbi.org/node/9438